Slate Path Capital LP Dexcom Inc Transaction History

Slate Path Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$75.49 - $124.16 $47.7 Million - $78.5 Million	632,000 New	632,000 $78.4 Million
Q2 2018 Aug 14, 2018	SELL	$17.54 - $25.22 $1.63 Million - $2.35 Million	-93,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.06 - $18.54 $300,380 - $426,420	23,000 Added 32.86%	93,000 $6.9 Million
Q4 2017 Feb 14, 2018	SELL	$11.12 - $15.38 $255,759 - $353,740	-23,000 Reduced 24.73%	70,000 $4.02 Million
Q3 2017 Nov 14, 2017	BUY	$11.36 - $18.98 $1.06 Million - $1.77 Million	93,000	93,000 $4.55 Million

1,016

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $30.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Slate Path Capital LP, based on Form 13F filings with the SEC.

Stay updated on Slate Path Capital LP with notifications on news.